Information Provided By: 
Fly News Breaks for December 17, 2018
BLCM
Dec 17, 2018 | 07:45 EDT
Bellicum Pharmaceuticals presented "encouraging" initial clinical data for the first-in-class GoCAR-T, BPX-601 in advanced pancreatic cancer at a conference late last week, Wells Fargo analyst Jim Birchenough tells investors in a research note. The company reported no cytokine release or neurotoxicity and the adverse event profile that was mild to moderate grade, adds the analyst. He keeps an Outperform rating on Bellicum with a $23 price target.
News For BLCM From the Last 2 Days
There are no results for your query BLCM
